Prednisone Articles
Ulcerative colitis drug market will nearly double to $2.1 billion in 2018 in top seven markets
15 February 2010
Sanofi-Aventis and Regeneron discontinue one Ph III study of aflibercept
14 September 2009
Helsinn's CINV drug effective in NHL patients
8 June 2009
UPDATE: UK doctors warn on Internet drug sales: 25% have treated related adverse effects
20 April 2009
Nitec's Lodotra has first launch in Germany
14 April 2009
Nitec licenses Lodotra to Mundipharma
2 April 2009
Ph III trial of Nitec's Lodotra completes recruitment
16 March 2009
Strong Ph II data for Cougar's abiratenone
9 March 2009
Strong interim Ph II data on Poniard's picoplatin
9 March 2009
Promising initial Ph II data on Ascenta's AT-101
9 March 2009
Stock Commentary - Europe - week to Jan 19, 2009
19 January 2009
Skyepharma up 14% on Lodotra recommendation
12 January 2009
Takeda drops Cell's GVAX after deaths
15 December 2008
FDA clears Celgene's first placenta-derived stem cell clinical study
17 November 2008
Japan stock market week to Oct 27, 2008
3 November 2008
Nitec secures 24M SwFr funding
6 October 2008
EC approves expanded indication for Velcade
15 September 2008
Millennium publishes results of VISTA trial
8 September 2008
Skyepharma further reduces loss in first half
8 September 2008
Japan stock market week to Sept 1, 2008
8 September 2008
Cell Genesys shares crash 70% after deaths in GVAX trial
1 September 2008
Satraplatin European MAA withdrawn
11 August 2008
Celgene pulls satraplatin MAA; weakening GPC
4 August 2008
Millennium/J&J's FDA approval for Velcade
30 June 2008
EC clears Celgene's Thalidomide in MM
28 April 2008
Phase III Lodotra study data positive
28 January 2008
Cell Genesys' GVAX trial gets IDMC go ahead
21 January 2008
Ph I/II US trial of tgACC94 resumes
3 December 2007
Nitec's Lodotra cuts RA morning stiffness
19 November 2007
Satraplatin fails to reach efficacy endpoint in Ph III trial
5 November 2007
Thalidomide improves survival rate in MM
15 October 2007
Poniard begins Ph II picoplatin HRPC trial
6 August 2007
EMEA accepts satraplatin MAA
6 August 2007
Millennium initiates Ph III trial of Velcade
23 July 2007
Web Rx drugs: "complex and emerging problem"
23 July 2007
Velcade produces 54% CR rate in MM
9 July 2007
Pharmion submits satraplatin MAA
2 July 2007
Revlimid combo could become MM standard of care
18 June 2007
Taxotere gets priority Japan review for mHRPC
18 June 2007
Satraplatin cuts progression in prostate cancer
11 June 2007
Satraplatin delays pain progression to 66 weeks
28 May 2007
GPC files satraplatin NDA with US FDA
23 April 2007
Nitec closes 32.0M SwFr fundraising round
9 April 2007
Satraplatin cuts Pain and PSA level at Ph III
2 April 2007
EMEA accepts Pharmion's Thalidomide MA
12 March 2007
Taxotere's efficacy in prostate cancer shown
5 March 2007
Nitec licenses Lodotra to Merck Pharma GmbH
19 February 2007
Ipsen licenses MSD's Adrovance in France
5 February 2007
Pharmion submits thalidomide to EMEA
29 January 2007
UK Internet drug logo "useless," say experts
13 November 2006
Stock Commentary - Europe - week to Oct 9, 2006
16 October 2006
Strong Ph III data for Nitec's Lodotra
9 October 2006
GPC shares rise 40% on strong satraplatin data
2 October 2006
GPC Biotech sees 2nd-qtr turnover of $7.1M
14 August 2006
GPC initiates new Ph II satraplatin trial
14 August 2006
GPC Biotech begins Ph II satraplatin study in NSCLC
7 August 2006
Strong data for Pharmion's thalidomide in MM
19 June 2006
FDA fast track for Cell Genesys' GVAX
15 May 2006
GPC Biotech's SPARC study gets DMB OK
1 May 2006
Genentech/Biogen Idec submit Rituxan sBLA
3 April 2006
Strong Ph I/II data for Cell Thera's pixantrone
27 March 2006
FDA approves Rituxan for NH lymphoma
20 February 2006
Spectrum enrolls Ph III satraplatin study
12 December 2005
A review of the 2005 meeting of the American College of Rheumatology
12 December 2005
Cell Genesys starts second Ph III GVAX trial
18 July 2005
Positive results for GPC Biotech's satraplatin
14 March 2005
Positive Ph III results for Spectrum's satraplatin
7 March 2005
Millennium and J&J start Velcade Ph III study
17 January 2005
EC clears Sanofi-Aventis' Taxotere for prostate cancer
8 November 2004
Aventis Taxotere gets OK for new use by FDA
23 August 2004
Pixantrone on FDA fast track for NHL
19 July 2004
FDA OKs Aventis' Taxotere for prostate cancer
24 May 2004
Rituximab meets goal in NHL trial
24 November 2003
GPC Biotech aiming to build broad oncology pipeline
24 November 2003
Satraplatin in Ph III
6 October 2003
GPC's satraplatin gets fast-track status
29 September 2003
GPC gets FDA OK for Ph III satraplatin trial
8 September 2003
Satraplatin effective in HR-prostate cancer
9 June 2003
InterMune's novel steroid helps in IPF
19 May 2003
IVAX to initiate Ph II trial of BNP-166 in Crohn's
1 April 2002
Mabthera/CHOP increase chance of NHL cure
13 December 2001
Update: Roche cancer drugs backed by CPMP
24 October 2001
CPMP recommends Roche's MabThera
22 October 2001
MabThera filed for aggressive NHL in EU
18 May 2001
MGI starts new prostate cancer trial
17 April 2001
Inex begins Phase II Onco TCS trial in NHL
27 March 2001
Rituxan combination ups survival in NHL; Zevalin update
6 December 2000
Rituxan combination ups survival in NHL
1 December 2000
Prednisone better than fluticasone, says study
8 September 2000
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
